Three independent discounted-cash-flow-style models value Neurocrine Biosciences, Inc. every trading day. 0 of 3 currently price NBIX above its market price.
| Free Cash Flow model | $101.38 |
| Excess Profit model | $144.89 |
| Residual Earnings model | $16.67 |
| Dividend Discount model | — |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | +13.7% |
| Net debt / EBITDA | -0.5× |
| Gross margin | +98.2% |
| Revenue CAGR | +24.3% |
| Cash conversion | 1.6× |
| Dividend yield | — |
| Buyback yield | -0.7% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open NBIX in StockKitty